TRO 19622 – 50 mg

Brand:
Cayman
CAS:
22033-87-0
Storage:
-20
UN-No:
Non-Hazardous - /

TRO 19622 is an orally bioavailable mitochondrial-targeted neuroprotective agent that binds to and inhibits opening of the mitochondrial permeability transition pore (mPTP).{39891,39892} It prevents mPTP opening induced by arachidonic acid (Item No. 90010) in HeLa cells when used at a concentration of 10 µM.{39891} TRO 19622 promotes survival of motor neurons in vitro in a concentration-dependent manner in the absence of neurotrophic factors (EC50 = 3.2 µM) and in vivo in a neonatal rat model of facial nerve axotomy when administered at a dose of 100 mg/kg per day.{39892} It delays onset of motor deficits and extends survival in the SOD1G93A transgenic model of amyotrophic lateral sclerosis (ALS). TRO 19622 (30 and 100 mg/kg) also increases the latency to paw withdrawal in a mechanical hyperalgesia test in rat models of streptozotocin-induced diabetic and vincristine-induced neuropathic pain but not in models of acute, inflammatory, or injury-induced pain.{39893}  

 

Out of stock

SKU: 21264 - Category:

Description

A mitochondrial-targeted neuroprotective agent; binds to and inhibits mPTP opening; prevents arachidonic acid-induced mPTP opening in HeLa cells at 10 µM; promotes survival of motor neurons in vitro in the absence of neurotrophic factors (EC50 = 3.2 µM); promotes survival of motor neurons in vivo in a neonatal rat model of facial nerve axotomy at 100 mg/kg per day; delays onset of motor deficits and extends survival in the SOD1G93A transgenic model of ALS; increases the latency to paw withdrawal in a mechanical hyperalgesia test in rat models of streptozotocin-induced diabetic and vincristine-induced neuropathic pain at 30 and 100 mg/kg


Formal name: cholest-4-en-3-one, oxime

Synonyms:  NSC 21311

Molecular weight: 399.7

CAS: 22033-87-0

Purity: ≥95% (mixture of isomers)

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cell Biology|Mitochondrial Biology||Research Area|Neuroscience|Pain Research